Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019 - PubMed (original) (raw)

. 2022 May;29(5):352-365.

doi: 10.1111/jvh.13663. Epub 2022 Mar 15.

Affiliations

• PMID: 35274406
• DOI: 10.1111/jvh.13663

Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019

Nicolette Veracruz et al. J Viral Hepat. 2022 May.

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) contribute to significant healthcare burden globally. We aim to provide an updated and comprehensive analysis of global trends in the incidence and mortality of HBV and HCV related acute infections, cirrhosis and hepatocellular carcinoma (HCC). Estimates of annual cause-specific disease incidence and mortality for HBV and HCV were analysed using the 2010-2019 Global Burden of Diseases, Injuries and Risk Factors Study database. Three distinct disease states were evaluated: acute infections, cirrhosis and HCC. Age-standardized disease incidence and mortality were presented per 100,000 population and stratified by age, sex, year and 21 world regions. From 2010 to 2019, overall incidence of acute HBV declined by 19.3% (95% CI 4.1-32.0, p < .05) and HBV cirrhosis declined by 15.0% (95% CI 9.8-20.7, p < .05). Incidence of HCV cirrhosis increased by 5.6% (95% CI 0.3-10.2, p < .05) and HCV HCC remained stable. Incidence of acute HCV declined until 2015, after which it began increasing. From 2010 to 2019, overall mortality for HBV cirrhosis and HCV cirrhosis declined, whereas mortality for acute infections and HCC remained stable. Major differences in HBV and HCV incidence and mortality trends were observed when stratified by world regions. In conclusion, while our analyses of global trends in HBV and HCV incidence and mortality demonstrate encouraging trends, disparities in disease epidemiology were observed across world regions. These observations will identify regions and populations where greater focus and resources are needed to continue progressing towards viral hepatitis elimination.

Keywords: epidemiology; liver cancer; liver disease; vaccination; viral hepatitis.

© 2022 John Wiley & Sons Ltd.

PubMed Disclaimer

Similar articles

• Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years.
  Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Veracruz N, et al. Liver Int. 2022 Oct;42(10):2145-2153. doi: 10.1111/liv.15347. Epub 2022 Jul 4. Liver Int. 2022. PMID: 35753064
• Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019.
  GBD 2019 Europe Hepatitis B & C Collaborators. GBD 2019 Europe Hepatitis B & C Collaborators. Lancet Public Health. 2023 Sep;8(9):e701-e716. doi: 10.1016/S2468-2667(23)00149-4. Lancet Public Health. 2023. PMID: 37633679 Free PMC article.
• Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
  Li M, Wei Z, Su J, Wu X, Xie X, You H, Jia J, Kong Y. Li M, et al. J Med Virol. 2024 Jan;96(1):e29405. doi: 10.1002/jmv.29405. J Med Virol. 2024. PMID: 38235623
• Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.
  Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, de Martel C. Alberts CJ, et al. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):724-735. doi: 10.1016/S2468-1253(22)00050-4. Epub 2022 May 14. Lancet Gastroenterol Hepatol. 2022. PMID: 35576953 Free PMC article.
• Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
  Fattovich G, Stroffolini T, Zagni I, Donato F. Fattovich G, et al. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014. Gastroenterology. 2004. PMID: 15508101 Review.

Cited by

• Machine-Based Learning Hierarchical Cluster Analysis: Sex-Based Differences in Prognosis Following Resection of Hepatocellular Carcinoma.
  Resende V, Tsilimigras DI, Endo Y, Guglielmi A, Ratti F, Aldrighetti L, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Gleisner A, Martel G, Hugh T, Endo I, Shen F, Pawlik TM. Resende V, et al. World J Surg. 2023 Dec;47(12):3319-3327. doi: 10.1007/s00268-023-07194-z. Epub 2023 Sep 30. World J Surg. 2023. PMID: 37777670
• Dynamic Prediction of the Risk of Hepatocellular Carcinoma After DAA Treatment for Hepatitis C Patients.
  Ma X, Huang L, Yu M, Dong R, Wang Y, Chen H, Yu R, Huang P, Wang J. Ma X, et al. Cancer Control. 2025 Jan-Dec;32:10732748251316609. doi: 10.1177/10732748251316609. Cancer Control. 2025. PMID: 39957415 Free PMC article.
• Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.
  Calderon-Martinez E, Landazuri-Navas S, Vilchez E, Cantu-Hernandez R, Mosquera-Moscoso J, Encalada S, Al Lami Z, Zevallos-Delgado C, Cinicola J. Calderon-Martinez E, et al. J Clin Med Res. 2023 Apr;15(4):200-207. doi: 10.14740/jocmr4902. Epub 2023 Apr 28. J Clin Med Res. 2023. PMID: 37187717 Free PMC article. Review.
• Characteristics, treatment and care of pregnant women living with hepatitis B in England: findings from a national audit.
  Bailey H, Nastouli E, Webb S, Peckham C, Thorne C. Bailey H, et al. Epidemiol Infect. 2023 Mar 2;151:e50. doi: 10.1017/S0950268823000225. Epidemiol Infect. 2023. PMID: 36960728 Free PMC article.
• Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study.
  Glantzounis GK, Korkolis D, Sotiropoulos GC, Tzimas G, Karampa A, Paliouras A, Asimakopoulos AG, Davakis S, Papalampros A, Moris D, Felekouras E. Glantzounis GK, et al. Cancers (Basel). 2022 Sep 9;14(18):4387. doi: 10.3390/cancers14184387. Cancers (Basel). 2022. PMID: 36139548 Free PMC article.

References

REFERENCES

1. 1. Zeng DY, Li JM, Lin S, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol. 2021;75(3):547-556.
2. 1. Global progress report on HIV, viral hepatitis, and sexually transmitted infections, 2021. (July 15, 2021). WHO. https://www.who.int/publications/i/item/9789240027077
3. 1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.
4. 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
5. 1. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266.

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information